Psilocybin-Assisted Therapy for Intergenerational Trauma

Part of paid clinical trials in New York, New York.

Sponsor
Rachel Yehuda
Study ID
NCT06899165
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Psilocybin — DRUG
    Psilocybin 25mg, capsules taken orally under the supervision of two trained study therapists
  • Integration sessions — BEHAVIORAL
    weekly integration sessions (therapy) for 6 weeks

Study Details

This is an open-label psilocybin-assisted therapy study that will examine the safety and tolerability of psilocybin-assisted therapy in the offspring of genocide survivors with mood and anxiety disorders. The study will also investigate the efficacy of psilocybin-assisted therapy in reducing symptoms such as depression, anxiety and stress, as well as changes to the psychological effects of parental exposure to genocide, and changes to psychological resilience.

Key Dates

Start date
Aug 28, 2025
Status verified
Sep 2025
Primary completion
May 31, 2029
Completion
Jan 2, 2030

Study Design

Enrollment
100 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Psilocybin-Assisted Therapy
    Offspring of genocide survivors with mood and anxiety disorders will undergo weekly therapy sessions and will be given 2 doses of psilocybin at least 3 weeks apart.

Primary Outcome Measure

Columbia-Suicide Severity Rating Scale (C-SSRS) [ Time Frame: up to 23 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
The Parsons Research Center for Psychedelic HealingNew YorkNew York10025-

Find similar trials in New York, NY

By condition
Depression
By specialty
PsychiatryMental healthBehavioral health
By research site
The Parsons Research Center for Psychedelic Healing· New York, NY

Related Studies